Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis

•First detaled patient case report of amivantamab monotherapy active against EGFR triple mutation (L858R/T790M/G796S) in cis.•Symptomatic, biochemical, and molecular response were rapid after initiation of amivantamab.•Antibody therapy may be successfully against on-target EGFR TKI resistance regardless of the underlying resistance mutations.